局限期小细胞肺癌治疗的研究进展

Advances in study on the therapy for limited-stage small cell lung cancer

小细胞肺癌(small cell lung cancer,SCLC)目前被分为两期:局限期小细胞肺癌和广泛期小细胞肺癌。局限期小细胞肺癌(limited-stage SCLC,LS-SCLC)指肿瘤局限于一侧胸腔,与原发灶覆盖同一放射野;目前,30%~40%SCLC患者属于局限期,LS-SCLC患者中位生存期为15~20个月,两年生存率为20%~40%。对于LS-SCLC患者,指南中推荐给予同步放化疗。对于完全缓解或已手术切除的I期LS-SCLC患者给予预防性脑放疗治疗。但对于SCLC,靶向药物还停留于研究阶段,缺少临床试验证实其疗效。

Small cell lung cancer （SCLC） are divided into lir^ited and extensive stage diseases. Limited-stage SCLC （LS-SCLC） is confined to the ipsilateral hemithorax and within a single radiotherapy region, 30%-40% of patients with SCLC are limited stage. The median ranges of survival for patients with LS-SCLC is from 15 to 20 months. Approximately 20%-40% of patients with LS-SCLC can survive for two years. According to the guidelines, patients with LS-SCLC should be treated with combined concurrent chemoradiotherapy and patients with LS-SCLC achieving a complete remission or patient with stage I disease who have had resection should be offered prophylactic cranial irradiation （PCI）. Whereas in SCLC, targeted therapies is still in the early stage and few clinical trial data is available to support its effect.